Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer (RNA-seq)

ABSTRACT: Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer (RNA-seq)

PROVIDER: PRJNA591704 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10528900.fastq.gz	Fastqsanger.gz
	SRR10528901.fastq.gz	Fastqsanger.gz
	SRR10528902.fastq.gz	Fastqsanger.gz
	SRR10528903.fastq.gz	Fastqsanger.gz
	SRR10528904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 78

Similar Datasets

Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer

Project description:Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer

| PRJNA591580 | ENA

Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer (ATAC-seq)

Project description:Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer (ATAC-seq)

| PRJNA591705 | ENA

Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer (ATAC-seq)

Project description:We present paired ATAC and RNA-sequencing from EGFR-driven lung cancer cell lines genetically modified to lose tumor suppressors RB1 and/or PTEN, and study the acute response of these cell lines to FDA-approved chemical inhibitors of EGFR

2021-06-01 | GSE140940 | GEO

Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer (RNA-seq)

Project description:We present paired ATAC and RNA-sequencing from EGFR-driven lung cancer cell lines genetically engineered to lose the tumor suppressors RB1 or RB1 with PTEN, and study the acute response of these cell lines to FDA-approved chemical inhibitors of EGFR

2021-06-01 | GSE140941 | GEO

Chromatin and transcriptome remodeling under EGFR chemical inhibition in lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-06-01 | GSE140942 | GEO

Global transcriptional profiling of HCC827 lung adenocarcinoma cells in response to EGFR inhibition

Project description:mRNA sequencing of EGFR mutant HCC827 lung adenocarcinoma cells were treated with erlotinib (EGFR inhibitor) for 24hr to profile and characterize dysregulated pathways in response to EGFR inhibition

2021-06-24 | GSE178755 | GEO

Targeting osteoblastic Mig6-EGFR signaling ameliorates osteoarthritis progression via inhibiting aberrant subchondral bone remodeling

Project description:Aberrant subchondral bone remodeling is a critical factor in osteoarthritis (OA) pathogenesis. We observed significant downregulation of Mitogen-induced gene-6 (Mig6) and upregulation of EGFR phosphorylation in subchondral bone osteoblasts, strongly correlating with OA severity in human and animal models. Mig6 is the most important factor mediating mechanical stress-activated EGFR, which inhibits osteogenic activity and modulates mechano-responsiveness. Osteoblast-specific Mig6 deletion exacerbated OA progression by promoting subchondral bone remodeling, whereas gefitinib-mediated inhibition of EGFR phosphorylation attenuated OA symptoms in mice, rats, and Mig6 knockout rats. Furthermore, loss of osteoblastic Mig6 disrupted the subchondral bone microenvironment, increasing inflammation, angiogenesis, and neuronal activity. Mechanistically, aberrant mechanical loading downregulated Mig6, activating phosphorylation of EGFR and the downstream JAK-STAT3 pathway, thereby promoting subchondral bone remodeling and accelerating OA progression. These findings reveal a novel mechanism by which osteoblastic Mig6 regulates subchondral bone remodeling in OA, highlighting Mig6 as a potential therapeutic target.

2025-07-31 | GSE302025 | GEO

Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy

Project description:Treatment of lung adenocarcinomas (LUAD) that exhibit activated epidermal growth factor receptor (EGFR) with EGFR tyrosine kinase inhibitors (TKI) has limited efficacy. Assessment of the impact of EGFR TKI on the LUAD surfaceome remodeling revealed potential therapeutic targets. We identified placental type alkaline phosphatase (ALPP) which has restricted expression in normal tissues, among upregulated surface proteins following EGFR TKI treatment of both TKI sensitive as well as resistant cells. Upregulation of ALPP with EGFR TKI resulted from activation of FoxO3a. The combination of EGFR TKI plus ALPP antibody conjugated with monomethylauristatin F enhanced tumor killing in osimertinib-sensitive and osimertinib-resistant LUAD models compared to either treatment alone. Our findings point to surfaceome remodeling induced with an established cancer therapy as a means for the development of more effective combination therapies.

2025-10-09 | PXD069074 | Pride

EGFR Mutation Promotes Glioblastoma Through Epigenome and Transcription Factor Network Remodeling

Project description:Epidermal Growth Factor Receptor (EGFR) gene amplification and mutations are the most common oncogenic events in Glioblastoma (GBM), but the mechanisms by which they promote aggressive tumor growth are not well understood. Here, through integrated epigenome and transcriptome analyses of cell lines, genotyped clinical samples and TCGA data, we show that EGFR mutations remodel the activated enhancer landscape of GBM, promoting tumorigenesis through a SOX9 and FOXG1-dependent transcriptional regulatory network in vitro and in vivo. The most common EGFR mutation, EGFRvIII, sensitizes GBM cells to the BET-bromodomain inhibitor JQ1 in a SOX9, FOXG1-dependent manner. These results identify the role of transcriptional/epigenetic remodeling in EGFR-dependent pathogenesis and suggest a mechanistic basis for epigenetic therapy. ChIP-Seq for H3K27ac, H3K4me1, and H3K4me3, and RNA-seq for Glioblastoma (GBM) cells and/or tissues with or without EGFRvIII mutation.

2015-09-14 | E-GEOD-72468 | biostudies-arrayexpress

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer

Project description:Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by non-genetic mechanisms. Here, we define the chromatin accessibility and gene regulatory signatures of osimertinib sensitive and resistant EGFR-mutant cell and patient-derived models and uncover a role for mammalian SWI/SNF chromatin remodeling complexes in TKI resistance. By profiling mSWI/SNF genome-wide localization, we identify both shared and cancer cell line-specific gene targets underlying the resistant state. Importantly, genetic and pharmacologic disruption of the SMARCA4/SMARCA2 mSWI/SNF ATPases re-sensitizes a subset of resistant models to osimertinib via inhibition of mSWI/SNF-mediated regulation of cellular programs governing cell proliferation, epithelial-to-mesenchymal transition, epithelial cell differentiation, and NRF2 signaling. These data highlight the role of mSWI/SNF complexes in supporting TKI resistance and suggest potential utility of mSWI/SNF inhibitors in TKI-resistant lung cancers.

2023-08-03 | GSE202863 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data